A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
← catalyst calendarNCT07578571 · readout ≤ 896 d
Sponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
175estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-21 | actual | When the study began enrolling |
| Primary completion | Jan 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Breast Cancer
- Esophageal Cancer
- Stomach Cancer
- Cancer
Intervention
- Drug: IM-1617
Primary outcomes
what the primary-completion date above is the date OFEvaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs)
measured Through 30 days after last dose of study treatment; approximately 12 months
Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs of interest (AEIs)
measured Through 30 days after last dose of study treatment; approximately 12 months
Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs leading to discontinuation
measured Through 30 days after last dose of study treatment; approximately 12 months
Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of death
measured Through 30 days after last dose of study treatment; approximately 12 months
Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed